Skip to main content
OpenTrials
Completed

NCT Number: NCT02922920

Effects of Tart Cherry Juice on the Body

Tart cherries are a rich source of antioxidants. Studies have shown that tart cherries exert anti-oxidative and anti-inflammatory properties. The purpose of this study is to learn about the effects of drinking tart cherry juice on cardiovascular and cognitive health.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Risk Factors Age-related Cognitive Decline

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Delaware

Newark, Delaware, 19716, United States

About this study

Thirty-seven older adults were randomly assigned to drink 16 oz per day of either tart cherry juice or placebo drink for 12 weeks. Blood and urine samples were collected at baseline and 12 weeks to assess biomarkers. Physical activity and 3-day diet records were also collected throughout the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 65-80

Exclusion criteria

  • Allergic to tart cherries
  • Heavy smoker
  • Taking medications that affect cognitive function
  • History of neurological disorders
  • History of traumatic brain injury
  • History of stroke
  • Clinical diagnosis of diabetes
  • Clinical diagnosis of Alzheimer's Disease/Dementia
  • GI disease
  • Kidney disease
  • Liver disease
  • Cancer

Treatment and study plan

Tart cherry juice

Other

16 fl. oz of tart cherry juice

Placebo

Other

16 fl. oz of placebo

Primary outcomes

  1. Cognitive function

    Time frame: Baseline and 12 weeks

    Change from baseline in cognitive test performance at 12 weeks

Secondary outcomes

  1. Cardiovascular risk factors

    Time frame: Baseline and 12 weeks

    Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in cardiovascular risk factors including blood lipid profiles, atherogenic risk ratios, blood glucose, hemoglobin A1c, insulin, and blood pressure at 12 weeks.

  2. Oxidative stress markers

    Time frame: Baseline and 12 weeks

    Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in plasma 8-oxoguanine (ng/ml), plasma 8-hydroxy-2deoxy-guanosine (ng/mL), plasma hydroxynonenal (ng/ml), and plasma malondialdehyde (pmole/L) at 12 weeks.

  3. Inflammatory markers

    Time frame: Baseline and 12 weeks

    Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in plasma tumor-necrosis factor-α (pg/mL) and plasma high-sensitivity C-reactive protein (ng/mL) at 12 weeks.

Sponsors and collaborators

Lead sponsor

University of Delaware

Other

Registry information

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 4, 2016
Registry last updated
Oct 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.